Genetics in anti-platelet treatment.

Genetics in anti-platelet treatment.
Curr Pharm Des. 2016 May 31;
Authors: Raut JS, Karuppayil SM, Gazouli M
Abstract
Anti-platelet drugs are necessary in treating patients with coronary artery disease, ischemic stroke and peripheral arterial disease. However, despite the use of adequate anti-platelet therapy, some patients will experience a recurrent atherothrombotic vascular event. These patients are characterized as low- or non-responders to therapy. Individual responsiveness to anti-platelet therapy as the use of clopidogrel and/or aspirin varies widely among patients. Such an individual variability is mainly determined by environmental and genetic factors. In this review, we focused on the underlying genetic mechanisms that might influence response to anti-platelet drugs.
PMID: 27262329 [PubMed - as supplied by publisher]

Source: Current Pharmaceutical Design - May 30, 2016 Category: Drugs & Pharmacology Authors: Raut JS, Karuppayil SM, Gazouli M Tags: Curr Pharm Des Source Type: research